Vaccine development begins with choosing the right piece of a pathogen to show the immune system and then engineering everything around that choice so the body mounts a strong, durable, and specific defense. That process has grown far more precise in recent years. Researchers now use human antibody discovery, atomic-level protein engineering, and novel delivery systems to build vaccines against diseases that were previously out of reach. Understanding how each stage works reveals why some vaccines induce lifelong protection after a single dose while others need frequent boosters, and why the same shot can perform differently from one person to the next.
Finding the Right Target
The first decision in vaccine design is which molecular target, or antigen, to use. Older vaccines often relied on whole killed or weakened pathogens, which present the immune system with hundreds of molecules at once. Modern approaches try to narrow that down to the specific structures that protective antibodies actually recognize. A strategy called reverse vaccinology flips the traditional process: instead of starting with a pathogen and hoping the immune system finds the important bits, researchers start by studying people who have successfully fought off an infection, isolate their protective antibodies, and then work backward to identify exactly which part of the pathogen those antibodies bind to. High-throughput antibody sequencing and structural biology tools have made this feasible at scale, enabling the discovery of vaccine antigens that were previously impossible to identify through conventional methods.1PubMed Central. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Locking Proteins in the Right Shape
Identifying the right antigen is only the beginning. Many viral surface proteins exist in multiple shapes, and the shape that the immune system encounters before the virus infects a cell, called the prefusion conformation, often looks very different from the shape after infection. The prefusion form tends to expose the sites where the most potent neutralizing antibodies bind, which makes it the ideal vaccine target. The catch is that these prefusion structures are inherently unstable; they tend to snap into their post-infection shape on their own, losing the very features that make them useful.2PubMed. Precision vaccine design targeting the prefusion state of viral glycoproteins: advances in structural vaccinology
Structural vaccinology solves this by engineering mutations that lock the protein in place. For respiratory syncytial virus (RSV), researchers designed stabilized versions of the fusion glycoprotein that stayed in the prefusion conformation and triggered roughly ten-fold higher neutralizing antibody levels in animal models compared with earlier stabilized designs.3PubMed. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine A similar approach was applied to all four types of human parainfluenza virus at once: engineered disulfide bonds and cavity-filling mutations stabilized each virus’s fusion protein, and one of the stabilized constructs induced 200- to 500-fold higher neutralizing antibody levels in mice compared with the post-fusion version of the same protein.4PubMed Central. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4 These are not minor improvements; they represent the difference between a vaccine candidate that barely works and one that generates strong protection. The RSV vaccines that reached the market in 2023 were built on exactly this kind of prefusion-stabilization work.
Getting the Antigen Into the Body
Once a stable antigen is designed, the next challenge is delivering it effectively. The delivery platform determines how long the antigen sticks around, which cells encounter it first, and how much of it gets produced. Several platforms are in wide use, and each comes with trade-offs.
mRNA in Lipid Nanoparticles
mRNA vaccines deliver genetic instructions for cells to manufacture the antigen themselves. The mRNA is packaged in tiny fat bubbles called lipid nanoparticles (LNPs) that protect it from degradation and help it enter cells. The composition of those LNPs matters more than people realize. Recent research found that lowering the proportion of a key ingredient, the ionizable lipid, from the roughly 50 percent used in current formulations down to about 30 percent actually produced significantly higher protein expression both in lab dishes and in animals. The improvement was not because cells took up more particles or because the mRNA escaped from internal compartments more efficiently; it appeared to come from how readily the mRNA separated from the lipid shell once inside the cell, a step that had been underappreciated.5PubMed Central. Mechanistic insights into mRNA-LNP interactions: role of ionizable lipid content in regulating mRNA intracellular release and translation
Viral Vectors and Preexisting Immunity
Adenovirus-based vaccines use a harmless virus as a delivery truck. The vector infects cells and causes them to produce the vaccine antigen. A well-known problem is that many people already carry antibodies against common adenoviruses from past natural infections, and those antibodies can intercept the vector before it does its job. Studies in mice have shown that even antibodies that fail to neutralize a modified adenovirus vector in the lab can still impair its ability to deliver a payload and stimulate immune responses inside a living animal, meaning standard lab tests may underestimate how much trouble preexisting immunity causes.6PubMed Central. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo That said, the impact depends on the level of preexisting antibodies. Low levels of prior immunity did not meaningfully reduce protection in animal experiments, and even high levels could be overcome by increasing the vaccine dose or changing the route of delivery.7PLOS ONE. Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine
Nanoparticle Displays
Another strategy arranges many copies of an antigen on the surface of a particle. This arrangement mimics the repetitive surface patterns found on real viruses, and B cells respond to it much more forcefully. When B cells encounter antigen displayed in a multivalent pattern on virus-sized particles, the display acts as a standalone danger signal: it triggers a unique signaling mode that bypasses the usual requirement for help from T cells, enhancing B cell activation, survival, and proliferation far beyond what soluble antigen achieves.8PubMed Central. Multivalent virus-like epitope display amplifies BCR signaling independent of avidity Nanoparticle-based scaffolds, including engineered DNA origami structures, exploit this principle to drive stronger antibody responses.9PubMed Central. Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds
Adjuvants and Danger Signals
A purified protein antigen on its own is often too quiet for the immune system to take seriously. Adjuvants are ingredients added to vaccines specifically to amplify the response. Aluminum salts, the oldest and most widely used adjuvant, work through several mechanisms. When immune cells swallow aluminum particles, the internal disruption activates an inflammatory pathway called the NLRP3 inflammasome, leading to the release of signaling molecules that recruit and activate more immune cells.10PubMed Central. Mechanism of immunopotentiation and safety of aluminum adjuvants11PubMed Central. Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3 Aluminum also binds to the outer membranes of dendritic cells and triggers the release of warning molecules from damaged tissue at the injection site.
Newer adjuvant strategies combine multiple immune-activating ingredients. Combination adjuvants that pair aluminum salts with molecules that stimulate different immune sensors, or oil-in-water emulsions blended with immune-stimulating compounds, can engage distinct molecular pathways simultaneously. The result is additive or synergistic effects on the innate immune response, which translates to stronger and sometimes qualitatively different adaptive immunity downstream.12PubMed. Combination adjuvants: clinical value and mechanisms of action The high-dose flu vaccine and the shingles vaccine both owe their effectiveness in older adults partly to more potent adjuvant systems.
How the Immune System Reads a Vaccine
After a vaccine is injected, dendritic cells at the injection site pick up the antigen and carry it to lymph nodes, where the adaptive immune response gets organized. Dendritic cells chop the antigen into small fragments and display those fragments on their surfaces for T cells to inspect. A process called cross-presentation allows dendritic cells to display fragments from an externally captured antigen in a way that activates killer T cells, the same type of cell normally activated only by internally produced proteins like those from a viral infection.13PubMed Central. Cross-presentation of exogenous antigens on MHC I molecules This is especially relevant for subunit vaccines, which lack the ability to infect cells directly. Designing formulations that promote cross-presentation is an active area of research, particularly for pediatric vaccines, because much less is known about how efficiently newborn and infant immune cells carry out this process compared with adult cells.14PubMed Central. Vaccine-Induced CD8+ T Cell Responses in Children: A Review of Age-Specific Molecular Determinants Contributing to Antigen Cross-Presentation
Inside the lymph node, a specialized subset of helper T cells called T follicular helper cells plays a critical coordinating role. These cells support B cells in structures called germinal centers, where B cells undergo rounds of mutation and selection to produce increasingly effective antibodies. A reduction in the number of these helper cells, or a shift in their characteristics, can impair both the quality and the persistence of the antibody response.15PubMed Central. Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response
Building Lasting Memory
The ultimate goal of vaccination is durable protection, and that depends on the formation of long-lived memory cells. Some of the most important are long-lived plasma cells, antibody factories that settle into survival niches in the bone marrow and can persist for decades, continuously secreting antibodies without needing to re-encounter the pathogen. Research using genetic time-stamping in mice found that these cells accumulate in the bone marrow at a roughly constant rate, about one cell per hour over several weeks after a single immunization.16PubMed. Long-lived plasma cells accumulate in the bone marrow at a constant rate from early in an immune response
Survival in the bone marrow is not passive. Plasma cells depend on signals from their local environment, and newly arriving cells must compete with established residents for limited space. A surface molecule called CD138 turns out to regulate this competition: cells with higher CD138 levels adhere more effectively to the bone marrow niche, outcompeting newer arrivals with lower levels. This dynamic competition between new and pre-existing plasma cells shapes how long antibody responses last and whether booster shots successfully add to the existing pool or simply replace it.17PubMed Central. CD138 and APRIL regulate plasma cell survival, competition, and retention in the bone marrow niche Inflammation, infection, and aging can all remodel this niche environment, potentially displacing previously established memory.18PubMed. Dynamic organization of the bone marrow plasma cell niche
Where You Inject Matters
Most vaccines are injected into muscle, which generates strong systemic immunity: antibodies circulating in the bloodstream, memory cells ready to mobilize. But infections caused by respiratory viruses begin at mucosal surfaces, where circulating antibodies are less concentrated. Intranasal vaccination addresses this gap. In mouse models of influenza, intranasal delivery established a population of antibody-secreting cells directly in the lung tissue, producing a class of antibodies called IgA that are specialized for mucosal defense. These lung-resident cells included tissue-resident memory B cells, plasmablasts, and plasma cells. The same protein-based vaccine given by injection into muscle or the abdominal cavity failed to produce this local IgA response.19PubMed Central. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA This distinction explains why injected flu vaccines reduce severe disease effectively but are less reliable at preventing infection entirely: they do not plant defenses at the front door.
Immune Imprinting and Updating Vaccines
One of the thorniest problems in vaccinology is immune imprinting, sometimes called original antigenic sin. When your immune system first encounters a pathogen or vaccine, it builds a memory of that specific version. When a closely related but updated version comes along, the immune system tends to preferentially recall those original memory cells rather than building a fresh response from scratch. For influenza, this phenomenon has long been recognized as a factor that limits the effectiveness of repeated seasonal vaccination.20PubMed Central. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
The same challenge has emerged with COVID-19 boosters. After vaccination with an updated booster targeting the XBB.1.5 Omicron subvariant, the neutralizing antibody response was still dominated by memory B cells originally induced by the ancestral Wuhan strain spike protein, rather than by newly generated cells tailored to the updated variant. This imprinting persisted even in people who had experienced multiple Omicron infections and vaccinations.21PubMed Central. Persistent immune imprinting after XBB.1.5 COVID vaccination in humans The practical consequence is that simply swapping in a new variant’s sequence may not fully redirect the immune response. Vaccine designers are exploring strategies like longer intervals between doses, different antigen formats, or combinations of variant sequences to work around this imprinting effect.
Trained Immunity and the Innate Side
Vaccine development has traditionally focused on adaptive immunity, the T cells and B cells that remember specific pathogens. But it turns out that innate immune cells, the first responders that were long thought incapable of memory, can also be reprogrammed by certain vaccines. This phenomenon, called trained immunity, involves lasting changes in how innate immune cells are wired at the level of gene regulation and metabolism, making them respond more vigorously to a broad range of threats encountered later.22PubMed. Trained immunity: adaptation within innate immune mechanisms
The tuberculosis vaccine BCG is the most studied example. Subcutaneous BCG vaccination can induce memory-like changes in lung macrophages through an unexpected route: the vaccine causes shifts in the gut microbiome and its metabolic outputs, and those changes in circulating metabolites lead to the reprogramming of immune cells in the lung.23Nature Immunology. Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut–lung axis The effect is not uniform across everyone, though. Detailed profiling of people who received BCG showed that the vaccine most strongly enhanced innate immune function in individuals whose immune systems were relatively quiet at baseline. People who already had high immune activity before vaccination saw little additional boost, suggesting a ceiling effect rather than a runaway amplification.24Immunity. Multi-omics profiling and chromatin accessibility analysis of human immune responses to BCG vaccination
Why the Same Vaccine Works Differently in Different People
Even with a perfectly designed antigen, adjuvant, and delivery system, vaccine responses vary enormously between individuals. Two major sources of this variation are genetics and age.
Host Genetics
Your immune system’s ability to present vaccine antigens to T cells depends heavily on a group of genes called the human leukocyte antigen (HLA) complex. These genes are among the most variable in the human genome, and specific variants influence how well vaccine-derived protein fragments are displayed. In studies of COVID-19 vaccination, certain HLA-DQ variants were consistently associated with stronger antibody responses, and others with weaker ones. The effect tracked with how tightly those HLA molecules physically bind to fragments of the vaccine’s spike protein: variants with higher binding affinity to the vaccine peptides predicted better immunogenicity.25npj Vaccines. Associations between genetic variations of HLA and IGHV, vaccination schedule, and COVID-19 vaccine immunogenicity In a more vulnerable population, people on dialysis for kidney disease, several HLA variants were linked to complete failure to produce detectable antibodies after vaccination.26PubMed Central. The Effect of HLA Polymorphism on Immune Response to SARS-CoV-2 Vaccination Within an Infection-Naïve, Vulnerable Population With End-Stage Renal Disease This genetic variability is one reason population-level efficacy numbers do not tell the whole story for any individual.
Aging and Immunosenescence
Older adults respond less robustly to most vaccines. The aging immune system undergoes changes collectively known as immunosenescence: the pool of naive T cells shrinks, germinal center reactions become less efficient, and chronic low-grade inflammation can interfere with productive immune activation. This makes older populations both more vulnerable to infection and harder to protect through vaccination.27PubMed Central. Impact of Immunosenescence on Vaccine Immune Responses and Countermeasures Strategies to compensate include using higher antigen doses, stronger adjuvants, modified dosing schedules, and even lifestyle interventions like exercise and nutritional optimization.28PubMed Central. Immunosenescence and human vaccine immune responses The high-dose influenza vaccine licensed for people over 65 is one practical example of this approach.
Molecular Mimicry and the Safety Margin
One concern that has followed vaccine development since its earliest days is the possibility that a vaccine antigen could resemble a normal human protein closely enough to trigger an autoimmune reaction. This concept, molecular mimicry, describes a situation in which antibodies or T cells raised against a vaccine component accidentally cross-react with the body’s own tissues. It has been documented as a plausible mechanism in rare post-vaccination autoimmune events.29PubMed Central. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction Modern antigen design actively screens for sequences that overlap with human proteins, and computational tools allow researchers to flag potential mimicry risks before a candidate enters trials. The risk remains extremely low relative to the autoimmune consequences of the natural infections vaccines prevent, but it illustrates why antigen selection is never a purely immunological decision; safety considerations shape every step.
The Cold-Chain Problem for mRNA Vaccines
Even after a vaccine is designed and proven effective, getting it to patients intact presents its own set of challenges. mRNA vaccines are especially fragile. The mRNA molecule itself is prone to chemical breakdown, with hydrolysis being the primary driver of instability, and the lipid nanoparticle shell is sensitive to temperature, light, oxidation, and pH changes.30PubMed Central. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability31PubMed Central. Possible Mechanisms of mRNA-LNP Degradation: A Comprehensive Review This is why the first COVID-19 mRNA vaccines required ultra-cold storage at minus 60 to minus 80 degrees Celsius, creating massive logistical burdens for health systems worldwide and leaving many regions unable to use the technology. Ongoing work to understand and mitigate each degradation pathway is gradually relaxing these requirements, with newer formulations tolerating standard refrigerator temperatures for longer periods. But the fundamental fragility of mRNA means that stability engineering is not a secondary concern; it is as critical to global vaccine access as antigen design or clinical efficacy.